MA43872A - Procédé de traitement d'une glomérulopathie à c3 - Google Patents

Procédé de traitement d'une glomérulopathie à c3

Info

Publication number
MA43872A
MA43872A MA043872A MA43872A MA43872A MA 43872 A MA43872 A MA 43872A MA 043872 A MA043872 A MA 043872A MA 43872 A MA43872 A MA 43872A MA 43872 A MA43872 A MA 43872A
Authority
MA
Morocco
Prior art keywords
glomerulopathy
treatment
Prior art date
Application number
MA043872A
Other languages
English (en)
Inventor
Petrus Bekker
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA43872A publication Critical patent/MA43872A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MA043872A 2016-01-14 2017-01-12 Procédé de traitement d'une glomérulopathie à c3 MA43872A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US201662397527P 2016-09-21 2016-09-21

Publications (1)

Publication Number Publication Date
MA43872A true MA43872A (fr) 2021-05-19

Family

ID=59312069

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043872A MA43872A (fr) 2016-01-14 2017-01-12 Procédé de traitement d'une glomérulopathie à c3

Country Status (18)

Country Link
US (3) US20170202821A1 (fr)
EP (1) EP3402486B1 (fr)
JP (4) JP7339733B2 (fr)
KR (1) KR102767008B1 (fr)
CN (1) CN108601790B (fr)
AU (1) AU2017207359C1 (fr)
BR (2) BR112018014222A2 (fr)
CA (1) CA3010735C (fr)
ES (1) ES3026359T3 (fr)
IL (1) IL260539B (fr)
MA (1) MA43872A (fr)
MX (2) MX2022006069A (fr)
NZ (1) NZ744083A (fr)
RU (1) RU2742888C2 (fr)
SG (1) SG11201805828YA (fr)
TW (1) TWI791423B (fr)
WO (1) WO2017123716A1 (fr)
ZA (1) ZA201804513B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
EP3682879B1 (fr) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Procédés et intermédiaires pour la préparation d'antagonistes c5ar
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
EP3340983B1 (fr) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Composés aryle, hétéroaryle, et hétérocycliques pour le traitement de troubles immunitaires et inflammatoires
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
EP3661493A4 (fr) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. Régimes thérapeutiques pour le traitement de l'hémoglobinurie paroxystique nocturne
JP2020529227A (ja) * 2018-01-30 2020-10-08 プロクター アンド ギャンブル インターナショナル オペレーションズ エスエーＰｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｏｐｅｒａｔｉｏｎｓ Ｓａ 懸濁粒子を含む相安定で噴霧可能なフレッシュニング組成物
EP3814374A4 (fr) * 2018-05-25 2022-03-09 Achillion Pharmaceuticals, Inc. Biomarqueurs de néphropathie associés à la voie alternative du complément
EP3846803A4 (fr) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Composés macrocycliques pour le traitement de troubles médicaux
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
EP3856164B1 (fr) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Formes morphiques d'inhibiteurs du facteur d du complément
EP4487915A3 (fr) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Formulations de capsules
BR112021011727A2 (pt) 2018-12-17 2021-08-31 Achillion Pharmaceuticals, Inc Dosagem direcionada para o tratamento de distúrbios mediados do complemento
CN113784955B (zh) 2019-03-11 2025-02-14 因弗拉克斯有限责任公司 作为C5a受体调节剂的稠合哌啶基双环和相关化合物
WO2020198062A1 (fr) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médiés par le complément
AU2021321901A1 (en) * 2020-08-07 2023-03-09 Kira Pharmaceuticals (Suzhou) Ltd. Compounds as C5ar inhibitors
AU2021410668A1 (en) * 2020-12-21 2023-07-06 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
AU772477B2 (en) 1998-08-28 2004-04-29 Scios Inc. Inhibitors of p38-alpha kinase
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
US6713502B2 (en) 2000-05-05 2004-03-30 Smithkline Beecham Corporation Anti-infectives
CN1231464C (zh) 2000-08-10 2005-12-14 三菱制药株式会社 新型3－取代的脲衍生物及其药学应用
WO2002022556A1 (fr) 2000-09-14 2002-03-21 Mitsubishi Pharma Corporation Derives amides et utilisations associees
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
CA2457461C (fr) 2001-08-17 2013-12-24 Tanox, Inc. Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b
ES2323576T3 (es) 2001-09-21 2009-07-21 Mitsubishi Tanabe Pharma Corporation Derivados de 4-pirimidona 3-sustituida.
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
WO2003082828A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
JP2005530719A (ja) 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP1529046A1 (fr) 2002-08-08 2005-05-11 Boehringer Ingelheim Pharmaceuticals Inc. Composes benzimidazole substitues
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
EP1638935A1 (fr) 2003-06-19 2006-03-29 Pfizer Products Inc. Antagoniste de nk1
WO2005007087A2 (fr) 2003-07-03 2005-01-27 Neurogen Corporation Derives (heterocycloalkyl)methyle substitues de type azole utilises comme modulateurs des recepteurs c5a
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
NZ561613A (en) 2005-02-18 2010-12-24 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (fr) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Inhibiteurs de la kinase met
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
RS55192B1 (sr) 2005-11-24 2017-01-31 Dompé Farm S P A Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže
ES2965283T3 (es) * 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
WO2008022060A2 (fr) 2006-08-14 2008-02-21 Novartis Ag composés organiques et leurs utilisations
EP2077842A2 (fr) * 2006-10-31 2009-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'un antagoniste du récepteur egfr pour le traitement de la glomérulonéphrite
US20100190824A1 (en) 2007-06-29 2010-07-29 Prabhat Kumar Novel Substituted Piperidones as HSP Inducers
AU2009282480B2 (en) 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010025510A1 (fr) 2008-09-03 2010-03-11 Xenome Ltd Bibliothèques de conjugués peptidiques et leurs méthodes de fabrication
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
AU2013277154A1 (en) * 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof
DK2994488T3 (da) 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
EP3682879B1 (fr) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
WO2017176620A2 (fr) 2016-04-04 2017-10-12 Chemocentryx, Inc. Antagonistes de c5ar solubles
AU2021410668A1 (en) 2020-12-21 2023-07-06 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor

Also Published As

Publication number Publication date
BR112018014222A2 (pt) 2018-12-11
US11779576B2 (en) 2023-10-10
CA3010735C (fr) 2023-06-13
JP7788814B2 (ja) 2025-12-19
SG11201805828YA (en) 2018-08-30
MX2018008624A (es) 2018-12-10
US20170202821A1 (en) 2017-07-20
KR102767008B1 (ko) 2025-02-11
RU2018129378A (ru) 2020-02-14
CN108601790B (zh) 2026-01-27
US11285138B2 (en) 2022-03-29
ES3026359T3 (en) 2025-06-11
US20190201388A1 (en) 2019-07-04
JP2019501935A (ja) 2019-01-24
TW201726134A (zh) 2017-08-01
CN108601790A (zh) 2018-09-28
CA3010735A1 (fr) 2017-07-20
EP3402486B1 (fr) 2025-03-19
ZA201804513B (en) 2024-01-31
JP2021183625A (ja) 2021-12-02
MX2022006069A (es) 2023-01-12
WO2017123716A1 (fr) 2017-07-20
EP3402486A1 (fr) 2018-11-21
JP2024110998A (ja) 2024-08-16
EP3402486A4 (fr) 2019-08-28
BR122024002810A2 (pt) 2024-03-12
NZ744083A (en) 2022-07-01
KR20180102642A (ko) 2018-09-17
TWI791423B (zh) 2023-02-11
RU2742888C2 (ru) 2021-02-11
RU2018129378A3 (fr) 2020-05-20
AU2017207359C1 (en) 2022-09-01
JP2023126235A (ja) 2023-09-07
AU2017207359A1 (en) 2018-07-26
EP3402486C0 (fr) 2025-03-19
AU2017207359B2 (en) 2022-04-14
IL260539B (en) 2021-05-31
JP7339733B2 (ja) 2023-09-06
US20220354837A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
EP3402486A4 (fr) Procédé de traitement d'une glomérulopathie à c3
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA45192A (fr) Traitement d'association
EP3353841A4 (fr) Procédé de préparation et d'application de composites de carbone-sélénium
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3389657A4 (fr) Procédés de traitement de l'hyperalgésie
EP3386655C0 (fr) Procédé pour le traitement de déchets
EP3852631A4 (fr) Procédé d'imagerie
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3966554A4 (fr) Procédé d'identification d'une structure
EP3966555A4 (fr) Procédé d'identification d'une structure
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3717011A4 (fr) Procédé de traitement ou de prévention d'une lésion liée à l'ischémie-reperfusion
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3305732A4 (fr) Procédé de traitement d'eaux usées
EP3356033A4 (fr) Procédé d'hydrogénation catalytique d'halonitroaromatiques
MA42423A (fr) Procédé de préparation d'un revêtement
EP3684342A4 (fr) Procédé de traitement
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
EP3633713A4 (fr) Procédé de production d'une structure et structure
EP3498837A4 (fr) Procédé d'édition de génome
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple